| Name | FGF-401 |
|---|---|
| Synonyms |
FGF 401;FGF-401
N-{5-Cyano-4-[(2-methoxyethyl)amino]-2-pyridinyl}-7-formyl-6-[(4-methyl-2-oxo-1-piperazinyl)methyl]-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2~{H}-1,8-naphthyridine-1-cboxamide FGF401 N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-cboxamide EVER-4010001 1,8-Naphthyridine-1(2H)-cboxamide, N-[5-cyano-4-(2-methoxyethyl)amino]-2-pyridinyl]-7-formyl-3,4-dihydro-6-[(4-methyl-2-oxo-1-piperazinyl)methyl] 0997 NVP-FGF-401 FGF-401 (NVP-FGF401 N-{5-cyano-4-[(2-methoxyethyl)amino]pyridin-2-yl}-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-1,2,3,4-tetrahydro-1,8-naphthyridine-1-cboxamide Roblitinib FGF401( Roblitinib) 8-naphthyridine-1(2H)-cboxamide N-[5-Cyano-4-[(2-methoxyethyl)amino]-2-pyridinyl]-7-formyl-3,4-dihydro-6-[(4-methyl-2-oxo-1-piperazinyl)methyl]-1,8-naphthyridine-1(2H)-cboxamide Roblitinib(FGF-401) Roblitinib (FGF401) ,S8548 FGF-401 ISO 9001:2015 REACH Roblitinib, 10 mM in DMSO |
| Description | FGF-401 is an inhibitor of FGFR4 extracted from patent WO2015059668A1, compound example 83; has an IC50 of 1.9 nM. |
|---|---|
| Related Catalog | |
| Target |
FGFR4:1.9 nM (IC50) |
| In Vivo | FGF-401 is a FGFR4 inhibitor developed for the treatment of solid tumor. FGF-401 is a FGFR4 inhibitor in phase I/II clinical studies for the treatment of positive FGFR4 and KLB expresion solid tumors and hepatocellular carcinoma[1]. |
| References |
[1]. WO2015059668A1 |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 852.1±65.0 °C at 760 mmHg |
| Molecular Formula | C25H30N8O4 |
| Molecular Weight | 506.557 |
| Flash Point | 469.1±34.3 °C |
| Exact Mass | 506.239014 |
| LogP | -0.15 |
| Vapour Pressure | 0.0±3.2 mmHg at 25°C |
| Index of Refraction | 1.654 |
| Storage condition | -20℃ |